FDA Awards ICON with Project Validating PROs
ICON plc announced that the US FDA has awarded the company with a project validating three Patient Reported Outcomes instruments that will measure clinical endpoints in antibacterial drug trials.
ICON plc announced that the US FDA has awarded the company with a project validating three Patient Reported Outcomes instruments that will measure clinical endpoints in antibacterial drug trials.
Read the full release here
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III POETYK PsA Trials Show Significant Clinical Benefit with Sotyktu in Psoriatic Arthritis
June 13th 2025New data from the POETYK PsA-Phase III trial, presented at the 2025 EULAR Congress, demonstrate that Bristol Myers Squibb’s Sotyktu (deucravacitinib) significantly improves joint and skin symptoms in adults with active psoriatic arthritis, maintaining efficacy through 52 weeks of treatment.
